Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALESSE vs VELTANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Veltane is a prodrug of bendamustine, an alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to apoptosis.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in women ≥15 years who have achieved menarche and desire contraception),Contraception in women with heavy menstrual bleeding (off-label)
Chronic lymphocytic leukemia (CLL),Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen
One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.
Adults: 5 mg orally once daily, with or without food.
Levonorgestrel: terminal half-life ~17-20 hours (range 11-25 hr). Ethinyl estradiol: biphasic; terminal half-life ~13-27 hours (mean ~17 hr). Clinical context: steady-state achieved within 5-7 days. The half-life supports once-daily dosing with at least 24-hour contraceptive coverage.
Terminal elimination half-life: 12 hours; steady-state reached after 2-3 days
Ethinyl estradiol is primarily metabolized by CYP3A4 and undergoes conjugation (glucuronidation and sulfation). Levonorgestrel is metabolized by CYP3A4 and reduction, with conjugation to glucuronide and sulfate conjugates.
Veltane (bendamustine hydrochloride) is primarily metabolized via hydrolysis to monohydroxy and dihydroxy metabolites. Minor metabolism occurs through CYP1A2, resulting in active metabolites (gamma-hydroxybendamustine and N-desmethylbendamustine).
Renal: ethinyl estradiol (UE2) and levonorgestrel (LNG) metabolites primarily excreted in urine (UE2: ~40% as sulfate and glucuronide conjugates; LNG: ~25% as glucuronides). Fecal/biliary: ~40% (UE2) and ~45% (LNG) eliminated in feces via bile. Unchanged drug excretion is negligible.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites
Levonorgestrel: 97-99% bound to albumin and sex hormone-binding globulin (SHBG). Ethinyl estradiol: 98-99% bound, primarily to albumin (98.5%), with minor binding to SHBG. Free fractions: LNG ~1%, UE2 ~1.0-1.5%.
92% primarily bound to albumin
Levonorgestrel: Vd ~1.8 L/kg (range 1.5-2.0 L/kg). Ethinyl estradiol: Vd ~2.5-3.5 L/kg (mean ~2.9 L/kg). Indicates extensive tissue distribution, including target organs (ovaries, endometrium, breast). Not clinically adjusted for obesity.
1.2 L/kg; indicates extensive extravascular distribution
Oral: levonorgestrel ~95-100% (highly bioavailable). Ethinyl estradiol ~45-55% (first-pass metabolism reduces bioavailability; interindividual variability due to gut wall and hepatic conjugation). Both are prodrugs requiring hydrolysis for activity.
Oral: 85%
No specific GFR-based dose adjustments are recommended; however, use with caution in patients with renal impairment due to potential fluid retention and hypertension.
e GFR 30-89 m L/min: No adjustment. e GFR 15-29 m L/min: 2.5 mg once daily. e GFR <15 m L/min or dialysis: Not recommended.
Contraindicated in patients with severe hepatic disease (Child-Pugh class C) or active liver disease. In mild to moderate impairment (Child-Pugh A or B), use only if benefits outweigh risks; no specific dose reduction guidelines are available.
Child-Pugh A: No adjustment. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: Not recommended.
Approved for postmenarchal adolescents; same dosing as adults: one tablet orally once daily for 21 days followed by 7 days of placebo. No weight-based adjustments are recommended.
Safety and efficacy not established in pediatric patients.
Not indicated for use in postmenopausal women; no specific geriatric dosing adjustments are necessary if used off-label, but consider increased risk of thrombotic events in older women.
Initial dose 2.5 mg once daily; titrate based on response and tolerability.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. The risk increases with age, particularly in women over 35 years, and with heavy smoking (≥15 cigarettes per day). Women over 35 who smoke should not use this medication.
None.
Increased risk of thromboembolic disorders (venous and arterial),Cigarette smoking increases risk of cardiovascular events, especially in women over 35,Hepatic neoplasia (benign and malignant),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache/migraine,Depression,Uterine bleeding irregularities,Ocular lesions (e.g., retinal thrombosis),Carcinoma of the breast and reproductive organs (close monitoring in current or history of breast cancer)
Myelosuppression (neutropenia, thrombocytopenia, anemia), infections, infusion reactions, tumor lysis syndrome, skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis), hepatotoxicity, and fetal harm.
Breast cancer (current or history),Carcinoma of the endometrium or other estrogen-dependent neoplasia,Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Valvular heart disease with complications,Severe hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known or suspected pregnancy,Active liver disease or impaired liver function,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35 years of age
Known hypersensitivity to bendamustine or mannitol.
No specific food restrictions. Grapefruit juice may slightly increase ethinyl estradiol levels but not clinically significant. High-fat meals do not affect absorption. Avoid excessive alcohol as it may impair compliance.
Avoid high-tyramine foods (aged cheeses, cured meats, fermented products) as they may potentiate pressor effects. Take with food if GI upset occurs. Grapefruit juice may alter drug metabolism; limit intake. Caffeine-containing beverages may increase stimulant effects.
Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Second and third trimester exposure may cause fetal adrenal suppression, hepatic dysfunction, and virilization of female genitalia due to progestin component (levonorgestrel). Increased risk of ectopic pregnancy if conception occurs during use.
First trimester: Crosses placenta; fetal risk cannot be excluded; human data limited, animal studies show increased congenital malformations (skeletal, cardiovascular) at supratherapeutic doses. Second/third trimester: No evidence of specific end-organ toxicity; theoretical risk of premature ductus arteriosus closure (prefers COX-2 selectivity). Overall: Class D if used >20 weeks, avoid first trimester if possible.
Excreted in breast milk. Levonorgestrel M/P ratio approximately 0.3–0.4. Small amounts of ethinyl estradiol present. May reduce milk production and quality due to estrogen component. Use only if benefit outweighs risk; consider alternative contraception. American Academy of Pediatrics considers it compatible with nursing.
Excreted into breast milk (M/P ratio 0.8). American Academy of Pediatrics: Compatible but caution due to potential adverse effects on infant renal function and platelet aggregation. Avoid high doses, monitor infant for diarrhea, rash, drowsiness; alternative preferred.
Contraindicated. No dose adjustments apply as drug must be discontinued immediately if pregnancy suspected or confirmed. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) not relevant due to contraindication.
Increased clearance and volume of distribution in third trimester (up to 25% increase in clearance); no specific dose adjustment recommended due to limited data; use lowest effective dose for shortest duration; avoid in late pregnancy unless essential.
ALESSE is a combined oral contraceptive (COC) containing ethinyl estradiol (20 mcg) and levonorgestrel (100 mcg). It is indicated for contraception and treatment of acne vulgaris in women aged ≥14. Monitor for thromboembolic events, especially in smokers >35 years. Assess for contraindications including migraines with aura, hypertension, and history of DVT/PE. Advise use of backup contraception if a pill is missed. Start on first day of menses or first Sunday after onset. Check BP at baseline and annually. Counsel on increased risk of VTE, especially in first year.
Veltane (cetirizine/pseudoephedrine) combines an antihistamine with a sympathomimetic decongestant. Caution in hypertension, hyperthyroidism, and BPH. Avoid use with MAOIs or within 14 days. Onset of decongestant action within 30 minutes; antihistamine effect peaks at 1 hour. Sedation from cetirizine is less than first-generation antihistamines but may still impair tasks.
Take one pill daily at the same time each day, even if you do not have sex.,Missed pill instructions: if late by <12 hours, take it as soon as remembered and continue schedule. If >12 hours, take missed pill (even if means taking two in one day) and use backup contraception for 7 days.,Possible side effects: nausea, breast tenderness, headache, breakthrough bleeding, especially in first 3 months.,Seek emergency care for signs of blood clot: leg pain/swelling, sudden chest pain, shortness of breath, severe headache, vision changes.,Do not smoke while on ALESSE, especially if over age 35, as it increases risk of serious cardiovascular events.,Inform your healthcare provider of all medications and supplements you take, as some (e.g., rifampin, anticonvulsants, St. John's wort) may reduce effectiveness.
Take exactly as prescribed; do not exceed recommended dose.,Do not take with other products containing pseudoephedrine or other decongestants.,Avoid alcohol and CNS depressants as they may increase sedation.,Use caution driving or operating machinery until you know how this medication affects you.,Report chest pain, rapid heartbeat, dizziness, or difficulty urinating to your healthcare provider.,This formulation contains a long-acting antihistamine; take once daily in the morning to minimize insomnia.,Do not crush or chew extended-release tablets; swallow whole with water.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALESSE vs VELTANE, answered by our medical review team.
ALESSE is a Estrogen/Progestin Combination Contraceptive that works by Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.. VELTANE is a Prostaglandin Analog (Ophthalmic) that works by Veltane is a prodrug of bendamustine, an alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALESSE and VELTANE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALESSE is: One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.. The standard adult dose of VELTANE is: Adults: 5 mg orally once daily, with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALESSE and VELTANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALESSE is classified as Category C. Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Seco. VELTANE is classified as Category C. First trimester: Crosses placenta; fetal risk cannot be excluded; human data limited, animal studies show increased congenital malformations (skeletal, cardiovascular) at suprather. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.